Aurobindo Pharma Ltd’s consolidated net profit increased 19.7 per cent to Rs 712 crore in the third quarter ended December 31, 2018, as against Rs 595 crore in the same period last year.
The total revenue of the Hyderabad-based company went up by 21.5 per cent to Rs 5,270 crore (Rs 4,336 crore), according to a release.
The growth in revenue and profit was driven by 27.4 per cent growth in formulations sales in the US, supported by growth in other markets as well.
N Govindarjan, Managing Director, Aurobindo Pharma, said there was ``strong’’ growth across all business segments and markets. ``Our execution strength, pipeline evolution and recent acquisitions will drive future growth,’’ he added.
Aurobindo had also entered into a share subscription pact to invest Rs 15 crore in Synergy Remedies, by subscribing to additional equity shares. After the transaction, it would hold 19.9 per cent of the share capital of Synergy, it said in a separate filing to BSE.
Aurobindo’s scrip lost 1.15 per cent on the BSE on Friday and is trading at Rs 769.80.